The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.
about
Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management.ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasiaBrain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia.Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study.Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.Diode laser in the treatment of epistaxis in patients with hereditary haemorrhagic telangiectasia.Optimal management of hereditary hemorrhagic telangiectasia.The effect of anterior palatine blocks on bleeding in hereditary hemorrhagic telangiectasia nasal surgery.Treatment of the skin manifestations of hereditary hemorrhagic telangiectasia with pulsed dye laser.Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).Technique modifications for septodermoplasty: an illustrative case.Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.Endoglin: a critical mediator of cardiovascular healthEfficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease.Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia.Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2.Hereditary haemorrhagic telangiectasia: From symptomatic management to pathogenesis based treatment.Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide.Reply to Fernández-Fernández.Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study.Advances in the Medical Management of Vascular Anomalies.Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: a population based study.Bevacizumab treatment in hereditary hemorrhagic teleangiectasia.
P2860
Q27317227-77C92601-0FF4-4299-8CB3-7DC36DA8DD96Q33573626-A4069E38-2662-450F-A155-DBE61FB569C3Q33843008-955A3582-F172-4E86-A61A-54F0DCAAD3BFQ33976779-BA4051D1-EF6E-46E3-9B7D-149599292A86Q34013723-744267DF-9373-4687-808B-14220F9AAE81Q34078081-C1D298C7-E191-4CD7-A456-6C74A0CBF641Q34260695-AB1B4215-18D2-4095-BA57-980451CC97E4Q34327921-DEF836A1-6F09-4AEA-AB73-2CE1A31971DFQ34388065-84CE32DF-7DA7-48D3-9FF9-D957F850D4B5Q34719946-F1D23F86-22B0-4C32-A358-944EEAC39989Q34726819-0622F6BC-6436-4B61-BB45-C046014FD53BQ36245169-1A6D9AB9-87A0-412F-B184-3855B14CCC05Q36416717-D1A8F9C3-01F9-44FE-BE83-BDC03ED6AFC8Q36821724-DC0B1A59-3B19-4019-A85E-A8A23FDAC423Q36825271-8242F9DA-3D79-4253-B90D-4BC850AB97E3Q37846178-D62CD48C-33AD-4B18-895D-39B0DD1984FCQ37846182-7EAABF45-44B9-4A57-8069-12632C45EBD9Q37965478-5F12EB26-D833-422D-B305-A671C4999DE1Q37996922-7AABC005-5B5A-4424-8705-ED930BD8007BQ38354161-8E062874-22DE-47A9-B1BE-69BDBD96BB36Q38365380-A8FCE178-712D-43F4-8010-A033CB77832DQ42080847-CC9B30A7-5A70-41EE-83EF-F69D24E07079Q42352780-0AD9B3BE-C091-49D4-95F4-0B39EDCF990DQ43565795-F4FAFAF4-08A6-47D2-A2CC-6BF44C8EE497Q45802048-E43544A6-21C5-49B0-ABD6-399406F5BBD2Q46283167-02CEE328-4383-446F-BA4A-8FB8A2008921Q48191418-10465384-DD99-4C82-9E2C-01DDF0ADC0E3Q49711115-984414E7-E149-413B-8C9A-00051E96044AQ52993249-979CA5D4-B336-4468-9D16-C793ECBC3A97Q54701601-0A352350-A1AC-4214-9647-E8CE78F3DF16
P2860
The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The effect of bevacizumab (Ava ...... ry hemorrhagic telangiectasia.
@ast
The effect of bevacizumab (Ava ...... ry hemorrhagic telangiectasia.
@en
type
label
The effect of bevacizumab (Ava ...... ry hemorrhagic telangiectasia.
@ast
The effect of bevacizumab (Ava ...... ry hemorrhagic telangiectasia.
@en
prefLabel
The effect of bevacizumab (Ava ...... ry hemorrhagic telangiectasia.
@ast
The effect of bevacizumab (Ava ...... ry hemorrhagic telangiectasia.
@en
P2093
P921
P356
P1433
P1476
The effect of bevacizumab (Ava ...... ry hemorrhagic telangiectasia.
@en
P2093
Frank Miller
Jana Simonds
Terence M Davidson
P304
P356
10.1002/LARY.20159
P407
P50
P577
2009-05-01T00:00:00Z